Zymeworks Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Loss and Comprehensive Loss
(Expressed in thousands of U.S. dollars except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | ||
| Research and development collaborations (note 9) | $27,110 | $10,030 |
| Operating expenses: | ||
| Research and development | 35,738 | 32,042 |
| General and administrative | 16,985 | 15,790 |
| Total operating expenses | 52,723 | 47,832 |
| Loss from operations | (25,613) | (37,802) |
| Other income: | ||
| Interest income | 3,424 | 5,920 |
| Other income, net (note 10) | 49 | 304 |
| Total other income, net | 3,473 | 6,224 |
| Loss before income taxes | (22,140) | (31,578) |
| Income tax expense | (496) | (75) |
| Net loss | (22,636) | (31,653) |
| Other comprehensive income (loss): | ||
| Unrealized income (loss) on available for sale securities, net of tax of nil (note 5) | 546 | (1,121) |
| Total other comprehensive income (loss) | 546 | (1,121) |
| Comprehensive loss | $(22,090) | $(32,774) |
| Net loss per common share (note 4): | ||
| Basic | $(0.30) | $(0.42) |
| Diluted | $(0.30) | $(0.42) |
| Weighted-average common stock outstanding (note 4): | ||
| Basic | 75,171,020 | 76,214,833 |
| Diluted | 75,226,387 | 76,248,158 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.